Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

By Timothy R. Rebbeck, H. Lynch, S. Neuhausen, S. Narod, L. V. van’t Veer, J. Garber, G. Evans, C. Isaacs, M. Daly, E. Matloff and 2 more. New England Journal of Medicine, 2002

1,495 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/ba28931a7771791b710c409fe7193358eea8e5ed

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Barbara L. Weber
2. Timothy R. Rebbeck
3. M. King

In Oncology

1. Barbara L. Weber
2. Timothy R. Rebbeck

Citations in the corpus

• Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. (2006, background): “Clinical options for women at high genetic risk of breast cancer include screening starting at a young age,(19) the use of highly sensitive detection methods,(20) and prophylactic surgeries of the ovaries or breast.(21-27) Because prophylactic surgeries, while highly effective in reducing risk, are ”
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. (2004, background): “This effect is also seen in the 50% breast cancer risk reduction we reported in association with bilateral prophylactic oophorectomy [7,17].”
• Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers (2009, neutral): “…43.4 Kauff et al., 2002 (10) PC SIS 56/48 42/24 98/72 2.0 MYFU B1/2: RRSO: 54.5 B1/2: RRSO: 39.8 B1/2: 48.1 B1/2: No RRSO: 48.3 B1/2: No RRSO: 51.2 Rebbeck et al., 2002 (8) RC IMC 219/240 42/52 261/292 8.5 MYFU B1/2: RRSO: 52.5 B1/2: RRSO: 54.9 B1/2: 42.0 B1/2: No RRSO: 50.3 B1/2: No RRSO: 50.3…”
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “BRCA1 and BRCA2 mutation carriers benefit from prophylactic strategies including bilateral oophorectomy [10, 11], bilateral mastectomy with reconstruction [12] and chemoprevention, while the role of intensified surveillance is controversial [13].”